Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Interfaces between COVID-19 and immunotherapy in cancer patients

Is there a role for jak1/2 inhibitors in patients with severe COVID-19?

Date

12 Dec 2020

Session

Interfaces between COVID-19 and immunotherapy in cancer patients

Presenters

Stefan Constaniescu

Authors

S. Constaniescu

Author affiliations

  • Ludwic Cancer Research, 10017 - Brussels/BE
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings